United States Food and Drug Administration (USFDA) has concluded its audit at Jubilant Pharmova’s step down subsidiary -- Jubilant Draximage Inc’s Radiopharmaceutical manufacturing facility located at Montreal, Canada on April, 23, 2024. The USFDA has issued 5 observations pursuant to the completion of audit. The company will submit an action plan on the observations.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
